NeoRx adds to coffers

Radiotherapy pharmaceutical developer NeoRx has signed definitive agreements with new institutional investors for a private placement of $4.1 million.

The Seattle-based firm will be selling 3.3 million shares of common stocks and warrants to purchase an additional 1.3 million shares. NeoRx said it would use the proceeds to initiate clinical trials for its NX 473 product candidate, as well as other corporate objectives.

By staff writers
March 7, 2005

Related Reading

NeoRx files IND for radiotherapy agent, July 6, 2004

NeoRx, MURR in holmium-166 supply deal, March 22, 2004

NeoRx makes executive moves, December 8, 2003

NeoRx closes International Isotopes deal, December 8, 2003

Copyright © 2005

Page 1 of 461
Next Page